{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:35:20Z","timestamp":1793885720721,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U24HL138660"],"award-info":[{"award-number":["U24HL138660"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100026309","name":"National Marrow Donor Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026309","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008980","name":"Medical College of Wisconsin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-25-1-2146"],"award-info":[{"award-number":["N00014-25-1-2146"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtct.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:15:29Z","timestamp":1786518929000},"page":"1368.e1-1368.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges With Expansion of Cell and Gene Therapy: A Call for System-Level Action"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-2141","authenticated-orcid":false,"given":"Jeffery J.","family":"Auletta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwen E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-8374","authenticated-orcid":false,"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.010_bib0001","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jtct.2022.08.029","article-title":"Nomenclature for cellular and genetic therapies: a need for standardization","volume":"28","author":"Sharma","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0002","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.08.010_bib0003","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy: a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0004","unstructured":"FDA. FDA approves first gene therapies to treat patients with sickle cell disease. 2023. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0005","unstructured":"FDA. Approved cellular and gene therapy products. 2026. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0006","unstructured":"Tandem Meetings. Transplantation and cellular therapy meetings of ASTCT and CIBMTR. 2026. Available at: https:\/\/www.tandemmeetings.com\/. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0007","unstructured":"CIBMTR. Current uses and outcomes of cellular therapies in the U.S.: 2024 summary slides. 2025. Available at: https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0008","unstructured":"CIBMTR. Stem cell therapeutic outcomes database (SCTOD). 2026. Available at: https:\/\/cibmtr.org\/CIBMTR\/About\/Our-Impact\/SCTOD. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0009","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41409-022-01650-5","article-title":"Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis","volume":"57","author":"Maakaron","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-Sponsored Multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0011","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO-25-00856","article-title":"Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after mismatched unrelated donor peripheral blood stem cell transplantation","volume":"43","author":"Al Malki","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0012","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0013","first-page":"197","article-title":"Bone marrow transplantation activity in Europe 1990. European Group for Bone Marrow Transplantation (EBMT)","volume":"8","author":"Gratwohl","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.010_bib0014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41409-026-02919-9","article-title":"The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy","volume":"61","author":"Greco","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0015","unstructured":"ASGCT. Quarterly industry landscape report. 2026. Available at: https:\/\/www.asgct.org\/news-publications\/landscape-report. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0016","unstructured":"ASGCT. Gene, cell, & RNA therapy landscape report. 2025. Available at: https:\/\/www.asgct.org\/uploads\/files\/general\/Landscape-Report-Q4-2025.pdf. Accessed April 11, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0017","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/d41573-025-00180-1","article-title":"Cancer cell therapies: global clinical trial trends and emerging directions","volume":"24","author":"Benthani","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtct.2026.08.010_bib0018","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0019","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.08.010_bib0021","series-title":"Cancer Facts & Figures","first-page":"2026","year":"2026"},{"key":"10.1016\/j.jtct.2026.08.010_bib0022","unstructured":"Blood Cancer United. Facts 2024-2025. Updated Data on Blood Cancers. Published September 2025. Accessed February 26, 2026. BloodCancerUnited.org\/resources\/educational-resources\/publications\/booklet\/facts-updated-data-blood-cancers"},{"key":"10.1016\/j.jtct.2026.08.010_bib0023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtct.2026.08.010_bib0024","unstructured":"Technavio. CAR T-cell therapy market analysis North America, Europe, Asia, Rest of World (ROW)\u2014US, UK, China, Canada, Japan, Germany, France, India, Italy, South Korea\u2014Size and Forecase 2025-2029. 2025. Available at: https:\/\/www.technavio.com\/report\/car-t-cell-therapy-market-analysis. Accessed April 29, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0025","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41587-026-03241-x","article-title":"First CAR T for solid tumors","volume":"44","author":"Brief","year":"2026","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0026","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1017\/S174413311700055X","article-title":"Projecting shortages and surpluses of doctors and nurses in the OECD: what looms ahead","volume":"14","author":"Scheffler","year":"2019","journal-title":"Health Econ Policy Law"},{"key":"10.1016\/j.jtct.2026.08.010_bib0027","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/15271544241286083","article-title":"The healthcare workforce shortage of nurses and physicians: practice, theory, evidence, and ways forward","volume":"25","author":"Michaeli","year":"2024","journal-title":"Policy Polit Nurs Pract"},{"key":"10.1016\/j.jtct.2026.08.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.18999","article-title":"Immigration ban and the US health care workforce","volume":"9","author":"Ramesh","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2026.08.010_bib0029","unstructured":"New York Academy of Medicine. Response to stripping \"professional status\" as proposed by the Department of Education. 2025. Available at: https:\/\/nyam.org\/article\/response-to-stripping-professional-status-as-proposed-by-the-department-of-education\/. Accessed April 29, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0030","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jtct.2024.04.005","article-title":"Recruitment and retention of hematopoietic cell transplantation and cellular therapy physicians: a report from the ASTCT talent acquisition task force","volume":"30","author":"Sharma","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0031","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jcyt.2024.03.007","article-title":"Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances","volume":"26","author":"Hopewell","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.08.010_bib0032","unstructured":"Center for Strategic and International Studies The U.S. should strengthen STEM education to remain globally competitive. 2022. Available at: https:\/\/www.csis.org\/blogs\/perspectives-innovation\/us-should-strengthen-stem-education-remain-globally-competitive. Accessed April 24, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0033","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jcyt.2025.08.004","article-title":"Universities can do more to prepare the biomedical workforce for the cell-, tissue- and gene-manufacturing industry","volume":"27","author":"How","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.08.010_bib0034","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0035","unstructured":"FDA. Long-term follow-up after administration of human gene therapy products. 2020. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0036","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/OP-25-00062","article-title":"Outpatient administration of chimeric antigen receptor T-Cell Therapy Using Remote Patient Monitoring","volume":"21","author":"Majhail","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2026.08.010_bib0037","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/OP-25-00291","article-title":"Health care, physics, and finance: the complex equation of outpatient CAR T-cell therapy","volume":"21","author":"Farinella","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2026.08.010_bib0039","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.jtct.2023.03.007","article-title":"Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the center for international blood and marrow transplant research","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0040","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jtct.2024.09.004","article-title":"Proceedings of the 2024 third annual ASTCT-NMDP ACCESS initiative workshop","volume":"30","author":"Auletta","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0041","unstructured":"Census.gov. Income, poverty and health coverage in the United States: 2022. 2023. Available at: https:\/\/www.census.gov\/newsroom\/press-releases\/2023\/income-poverty-health-insurance-coverage.html. Accessed February 23, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0042","unstructured":"KKF. Racial and ethnic disparities in access to medical advancements and technologies. 2024. Available at: https:\/\/www.kff.org\/racial-equity-and-health-policy\/racial-and-ethnic-disparities-in-access-to-medical-advancements-and-technologies\/. Accessed February 23, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0043","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtct.2026.08.010_bib0044","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clml.2024.09.010","article-title":"Sociodemographic factors influencing access to chimeric antigen T-cell receptor therapy for patients with non-Hodgkin lymphoma","volume":"25","author":"Khare","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2026.08.010_bib0045","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2024015013","article-title":"Receiving CAR T-cells gets faster, but not for all in need","volume":"9","author":"Ramos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.010_bib0046","unstructured":"KFF. Putting $880 billion in potential federal Medicaid cuts in context of state budgets and coverage. 2025. Available at: https:\/\/www.kff.org\/medicaid\/putting-880-billion-in-potential-federal-medicaid-cuts-in-context-of-state-budgets-and-coverage\/. Accessed February 23, 2026."},{"issue":"6","key":"10.1016\/j.jtct.2026.08.010_bib0047","first-page":"737","article-title":"Breaking access barriers to autologous stem cell transplantation and chimeric antigen receptor T cell therapy in hematologic malignancies-an ASTCT-NMDP ACCESS Initiative","volume":"32","author":"Munshi","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0048","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0049","unstructured":"KFF ACA marketplace premium payments would more than double on average next year if enhanced premium tax credits expire. 2025. Available at: https:\/\/www.kff.org\/affordable-care-act\/aca-marketplace-premium-payments-would-more-than-double-on-average-next-year-if-enhanced-premium-tax-credits-expire\/. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0050","unstructured":"Fortune These GOP states would suffer the biggest blows if Affordable Care Act subsidies expire, analysts say. 2025. Available at: https:\/\/fortune.com\/2025\/11\/09\/aca-subsidies-republican-states-government-shutdown-affordable-care-act-obamacare-medicaid\/. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0051","unstructured":"Coherent Market Insights CAR T-cell therapy market analysis & forecast: 2026-2033. 2026. Available at: https:\/\/www.coherentmarketinsights.com\/market-insight\/car-t-cell-therapy-market-102. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0052","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood.2025030872","article-title":"Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries","volume":"147","author":"Ge","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.010_bib0053","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41409-024-02459-0","article-title":"Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0054","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1016\/S2352-3026(24)00170-4","article-title":"The development of academic CAR T cells","volume":"11","author":"Delgado","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0055","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2352-3026(24)00377-6","article-title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1\/2 study","volume":"12","author":"Jain","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0056","unstructured":"CIMMTR SCTOD requirements. 2026. Available at: https:\/\/cibmtr.org\/CIBMTR\/Data-Operations\/Center-Membership\/SCTOD-Requirements. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0057","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2024.06.010","article-title":"Leveraging hematopoietic cell transplant data and biorepository resources at the center for international blood and marrow transplant research to improve patient outcomes","volume":"30","author":"Bolon","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0058","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0059","unstructured":"FDA Cellular and gene therapy guidelines. 2025. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0060","unstructured":"CMS Coverage with evidence development. 2026. Available at: https:\/\/www.cms.gov\/medicare\/coverage\/evidence. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0061","unstructured":"CIBMTR Medicare coverage with evidence development (CED) studies. 2026. Available at: https:\/\/cibmtr.org\/CIBMTR\/Research\/Collaborations\/CED-Studies. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0062","unstructured":"CMS CGT (cell and gene therapy access) model. 2026. Available at: https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/cgt. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0063","unstructured":"CIBMTR CMS innovation center's cell and genet therapy (CGT) access model for sickle cell disease (SCD). 2026. Available at: https:\/\/cibmtr.org\/CIBMTR\/Collaborations\/CMMI. Accessed February 21, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0064","unstructured":"EBMT Registry. Available at: https:\/\/www.ebmt.org\/registry\/ebmt-registry. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0065","unstructured":"World Marrow Donor Association. Available at: https:\/\/wmda.info\/. Accessed June 8, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0066","unstructured":"World Marrow Donor Association Global trends report 2025. Available at: https:\/\/wmda.info\/wp-content\/uploads\/2026\/06\/GTR-2025-Summary-Slides-20260608.pdf. Accessed June 8, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0067","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jcyt.2025.04.060","article-title":"Shaping the future of cell and gene therapy workforce development: training of cell therapy processing personnel: perspectives from the International Society for Cell & Gene Therapy Lab Practices Committee","volume":"27","author":"Maryamchik","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2026.08.010_bib0068","unstructured":"International Society for Cell and Gene Therapy Workforce development and training. Available at: https:\/\/www.isctglobal.org\/archived\/resources\/training-programs. Accessed April 24, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0069","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2011.10.004","article-title":"The National Marrow Donor Program's Symposium on hematopoietic cell transplantation in 2020: a health care resource and infrastructure assessment","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2012.10.005","article-title":"Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative","volume":"19","author":"Denzen","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0071","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.bbmt.2017.11.015","article-title":"Burnout, moral distress, work-life balance, and career satisfaction among hematopoietic cell transplantation professionals","volume":"24","author":"Neumann","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0072","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/bloodadvances.2024013254","article-title":"OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R\/R LBCL","volume":"8","author":"Linhares","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.010_bib0073","doi-asserted-by":"crossref","first-page":"862.e1","DOI":"10.1016\/j.jtct.2026.02.057","article-title":"Outpatient versus inpatient axicabtagene ciloleucel CAR T-cell therapy in non-Hodgkin's lymphoma: insights from a US Multicenter Transplant and Cellular Therapy Network","volume":"32","author":"Battiwalla","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0074","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare utilization and cost trends for CAR T cell therapies across settings of care in the treatment of diffuse large B-cell lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2026.08.010_bib0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hon.3065","article-title":"A unique hub-and-spoke model to optimize patient management in lymphoma using novel CAR-T cell therapy in Southeast and South Asia","volume":"40","author":"Wei Inng Lim","year":"2022","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0076","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jtct.2025.07.017","article-title":"Assessing social determinants of health in transplantation and CAR-T recipients: expert panel recommendations from the survivorship special interest group of ASTCT","volume":"31","author":"Espinoza-Gutarra","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0077","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.2025.23059","article-title":"New guidance on responsible use of AI","volume":"335","author":"Palmieri","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2026.08.010_bib0078","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2022.09.020","article-title":"The ASTCT-NMDP ACCESS initiative: a collaboration to address and sustain equal outcomes for all across the hematopoietic cell transplantation and cellular therapy ecosystem","volume":"28","author":"Auletta","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0079","doi-asserted-by":"crossref","first-page":"957.e1","DOI":"10.1016\/j.jtct.2025.08.027","article-title":"Proceedings from the second reimagining caregiver workshop: addressing caregiver requirements for hematopoietic cell transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0080","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.jtct.2025.04.006","article-title":"Proceedings from the reimagining caregiver workshop: addressing caregiver requirements for hematopoietic cell transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0081","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jtct.2023.09.026","article-title":"Proceedings of the 2023 second annual ASTCT-NMDP ACCESS initiative workshop","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.010_bib0082","first-page":"1474","article-title":"Understanding diversity: an ASTCT-NMDP ACCESS initiative survey of the hematopoietic cell transplant and cellular therapy workforce in the United States","volume":"S2666-6367","author":"Pereda Ginocchio","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0083","doi-asserted-by":"crossref","first-page":"12.e1","DOI":"10.1016\/j.jtct.2025.09.031","article-title":"Physician advocacy for hematopoietic cell transplantation and cell therapy: overcoming challenges to reduce disparities and improve outcomes for patients","volume":"32","author":"Ghalehsari","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0084","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41409-024-02430-z","article-title":"Precision medicine results from equitable representation","volume":"60","author":"Gomez-Arteaga","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.010_bib0085","unstructured":"ASTCT ACCESS initiative. 2026. Available at: https:\/\/www.astct.org\/Advocacy\/ACCESS-Initiative. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0086","unstructured":"CAR T Vision. 2025. Available at: https:\/\/cartvision.com\/. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0087","unstructured":"CAR T Vision. Executive summary. 2025. Available at: https:\/\/cartvision.com\/executive-summary\/. Accessed April 26, 2026."},{"key":"10.1016\/j.jtct.2026.08.010_bib0088","unstructured":"BioCanRx Canada's immunotherapy network. 2026. Available at: https:\/\/biocanrx.com\/. Accessed April 26, 2026"},{"key":"10.1016\/j.jtct.2026.08.010_bib0089","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.08.010_bib0090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19(+) relapsed\/refractory malignancies","volume":"29","author":"Ortiz-Maldonado","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0091","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.19170","article-title":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"204","author":"Martinez-Cibrian","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0092","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3324\/haematol.2019.228577","article-title":"Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma","volume":"106","author":"Perez-Amill","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.010_bib0093","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.08.010_bib0094","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ymthe.2024.11.028","article-title":"ARI0003: Co-transduced CD19\/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Bachiller","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I","volume":"11","author":"Castella","year":"2020","journal-title":"Clinical Trial Front Immunol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0096","doi-asserted-by":"crossref","first-page":"e774","DOI":"10.1016\/S2352-3026(25)00258-3","article-title":"Establishing a sustainable academic point-of-care network for CAR T-cell therapy","volume":"12","author":"Olesti","year":"2025","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.08.010_bib0097","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/cts.12666","article-title":"The FDA's regulatory framework for chimeric antigen receptor-T cell therapies","volume":"12","author":"Marks","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jtct.2026.08.010_bib0098","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.jtct.2025.02.009","article-title":"Awakening from REMS: ASTCT 80\/20 ongoing recommendations for safe use of chimeric antigen receptor T cells","volume":"31","author":"Locke","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.08.010_bib0099","unstructured":"Factglobal.org FACT community immune effector cell standards. 2026. Available at: https:\/\/www.factglobal.org\/fact-standards\/. Accessed April 26, 2026."},{"issue":"4","key":"10.1016\/j.jtct.2026.08.010_bib0100","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013878","article-title":"Data-informed optimization of CAR T-cell therapy long-term follow-up","volume":"14","author":"Foss-Campbell","year":"2026","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.010_bib0101","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jtct.2026.02.054","article-title":"Advancing cell therapies for solid tumors: a pathway to overcome biological, operational, and regulatory hurdles","volume":"32","author":"Kirtane","year":"2026","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:20:26Z","timestamp":1793884826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666636726006135"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges With Expansion of Cell and Gene Therapy: A Call for System-Level Action","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}